

Research Article

Assessment of the Aging of the Brown Adipose Tissue by ^{18}F -FDG PET/CT Imaging in the Progeria Mouse Model $\text{Lmna}^{-/-}$

Zhengjie Wang ¹, Xiaolong Xu,² Yi Liu,¹ Yongheng Gao,¹ Fei Kang ¹, Baohua Liu ^{3,4,5}, and Jing Wang ¹

¹Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No. 127 West Changle Road, Xi'an 710032, China

²Department of Orthopaedics, Xijing Hospital, Fourth Military Medical University, No. 127 West Changle Road, Xi'an 710032, China

³Medical Research Center (MRC), Shenzhen University Health Science Center, Shenzhen 518060, China

⁴Department of Biochemistry and Molecular Biology, Shenzhen University Health Science Center, Shenzhen 518060, China

⁵Guangdong Key Laboratory for Genome Stability and Human Disease Prevention, Shenzhen University Health Science Center, Shenzhen 518060, China

Correspondence should be addressed to Fei Kang; fmmukf@qq.com; Baohua Liu; ppliew@szu.edu.cn, and Jing Wang; wangjing@fmmu.edu.cn

Received 11 December 2017; Revised 9 April 2018; Accepted 24 April 2018; Published 11 July 2018

Academic Editor: Barbara Palumbo

Copyright © 2018 Zhengjie Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Brown adipose tissue (BAT) is an important energy metabolic organ that is highly implicated in obesity, type 2 diabetes, and atherosclerosis. Aging is one of the most important determinants of BAT activity. In this study, we used ^{18}F -FDG PET/CT imaging to assess BAT aging in $\text{Lmna}^{-/-}$ mice. The maximum standardized uptake value (SUV_{Max}) of the BAT was measured, and the target/nontarget (T/NT) values of BAT were calculated. The transcription and the protein expression levels of the uncoupling protein 1 (UCP1), beta3-adrenergic receptor (β 3-AR), and the PR domain-containing 16 (PRDM16) were measured by quantitative real-time polymerase chain reaction (RT-PCR) and Western blotting or immunohistochemical analysis. Apoptosis and cell senescence rates in the BAT of WT and $\text{Lmna}^{-/-}$ mice were determined by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and by CDKN2A/p16INK4a immunohistochemical staining, respectively. At 14 weeks of age, the BAT SUV_{Max} and the expression levels of UCP1, β 3-AR, and PRDM16 in $\text{Lmna}^{-/-}$ mice were significantly reduced relative to WT mice. At the same time, the number of p16INK4a and TUNEL positively stained cells (%) increased in $\text{Lmna}^{-/-}$ mice. Collectively, our results indicate that the aging characteristics and the aging regulatory mechanism in the BAT of $\text{Lmna}^{-/-}$ mice can mimic the normal BAT aging process.

1. Introduction

Aging has been defined as the age-related deterioration of physiological functions of an organism. The main characteristic of the aging process is the gradual decline of the functions of the organ system. Brown adipose tissue (BAT) is an adipose organ which is responsible for maintaining the core temperature in small mammals and in newborn humans [1]. The functional status of BAT is closely related to obesity, type 2 diabetes, and atherosclerosis [2, 3].

Aging is one of the most important determinants of BAT activity [4]. Yoneshiro et al. has reported that cold-induced

brown fat activity is greatly decreased with aging [5]. Therefore, it is important to study the relationship between BAT functional status and aging. Since 1996, many long-term studies have investigated the relationship between BAT function and aging by assessing BAT-related indicators [6–8]. These indicators included cold-induced heat generation, cold tolerance, body temperature, and other macrophysiological parameters as well as molecular biomarkers, such as uncoupling protein 1 (UCP1), PPAR-g coactivator 1a (PGC1a), PR domain-containing 16 (PRDM16), and beta3-adrenergic receptor (beta3-AR) [6–8]. However, there are still some concerns regarding the above studies. Firstly,

the mice of the research model used in the above studies have normal aging rate, with a life duration of up to 32 weeks, so research takes long time, and the degree of aging is difficult to define [9]; secondly, the research method, the macroscopic physiological indicators, or microscopic molecular markers used in the above studies are only indirect indicators of the metabolic activity in the BAT and often do not accurately reflect the functional status of BAT. Thus, a visualized imaging method and a unified premature aging model are necessary to investigate the metabolic profile changes and the regulation mechanism of BAT aging.

Since 2003, the presence of adult BAT was confirmed by ^{18}F -FDG PET scanning [10]. Currently, ^{18}F -FDG PET/CT imaging is considered to be the “gold standard” in basic research and clinical studies for assessing BAT function *in vivo* [10–12] and has been widely used in the basics and clinical studies of BAT. The functional status of BAT can be directly calculated from the glucose metabolism activity levels [12].

Hutchinson–Gilford progeria syndrome (HGPS) is caused by a mutation in the *Lmna* gene, and the mouse model of HGPS used in this study is a widely used aging model in basic research studies [13–15]. Abbreviated as *Lmna*^{−/−} mice, these types of mice have demonstrated classical presenile manifestations in multiple organs, such as skin, liver, and kidneys [16, 17]. However, clinical evidence has shown that HGPS patients are free of cognitive deterioration in the central nervous system [18], which may be attributed to the inhibitory effect of the microRNA *miR-9* on progeria [19]. Therefore, progerin-induced aging is very likely to be organ specific. In order to assess the applicability of the *Lmna*^{−/−} mice model in BAT-related aging studies, we addressed the potential implication of the BAT function of *Lmna*^{−/−} mice in premature senility. Furthermore, whether the levels of BAT function measured by ^{18}F -FDG PET/CT uptake levels are related to the levels of the aforementioned molecular aging markers would provide additional information about the feasibility of using this mouse model in BAT-related aging research.

In this study, ^{18}F -FDG PET/CT imaging technique was used to qualitatively and quantitatively analyze the relationship between ^{18}F -FDG PET/CT imaging and BAT aging in *Lmna*^{−/−} mice. The relationship between the levels of the BAT-related molecular markers, UCP1 and β 3-AR, and ^{18}F -FDG uptake was examined. In addition, the mechanism of BAT function in *Lmna*^{−/−} mice was also studied.

2. Materials and Methods

2.1. Animal Preparation and ^{18}F -FDG Micro-PET/CT Imaging. *Lmna*^{−/−} mice were obtained from the Medical Laboratory Animal Department of The Fourth Military Medical University, and experiments were performed in accordance with the Animal Experimental Ethics Committee of The Fourth Military Medical University approved protocols. Aging mice were identified by PCR (Supplementary Figure 1). Mice were cold-treated under fasting conditions for a duration of 4 hours before they received one dose of ^{18}F -FDG [20], ensuring that the mice were fasting but with free access to water. 200–300 μCi of ^{18}F -FDG in


TABLE 1: Primers used in quantitative RT-PCR experiments.

Primer	Primer sequence (5'-3')
β -actin-S	GTGACGTTGACATCCGTAAAGA
β -actin-A	GTAACAGTCCGCCTAGAAGCAC
β 3-AR-S	CCTTCCGTCTGTCTTCTGTGTAG
β 3-AR-A	CTGTTGAGCGGTGGACTCTG
Ucp1-S	ACAGTAAATGGCAGGGGACG
Ucp1-A	CACGGGGACCTACAATGCTT
GLUT1-S	ACGCCCCCAGAAGGTTAT
GLUT1-A	GCGTGGTGAGTGTGGTGGAT
PRDM16-S	ATGGGATCCATGAAGAACGGT
PRDM16-A	CACGTCTACGGTGAACGGAA


150 μl of saline was intraperitoneally injected into each mouse. The mice were maintained in the cold for one additional hour after FDG injection and then scanned with a small-animal-dedicated micro-PET/CT system. The rectal temperature was measured using a PET/CT accessory. Once anesthesia was induced, the animals were moved onto mice beds with their heads resting within a conical face mask that continuously delivered 2% isoflurane at a flow rate of 1.5 L/min. An electric heating pad, provided by the small-animal PET/CT system, was placed under the animals to help maintain their body temperature. PET/CT data were acquired for 600 s for each mouse under continuous anesthesia. All PET/CT images were processed and analyzed using the Nucline nanoScan software (Mediso). For semi-quantitative analysis, three-dimensional (3D) regions of interest were carefully drawn and manually adjusted, according to the CT images, over the borders of the BAT on the small-animal PET images of each mouse. Three-dimensional round regions of interest were delineated on the lung as a nontarget (NT) reference. Tracer uptake rates by the BAT and the lung tissue were quantified as the maximum standardized uptake values (SUV_{Max}) using the formula: $\text{SUV}_{\text{Max}} = \text{maximum tissue activity concentration (Bq/mL)}/\text{injected dose (Bq)} \times \text{body weight (g)}$. The average uptake ratio (T/NT) of the mean BAT (T) over the mean lung tissue (NT) uptake was calculated and compared.

2.2. Quantitative Real-Time Reverse Transcription PCR. After the mice were sacrificed, total RNA was isolated from BAT using the Total RNA Kit I (Omega Bio-Tek, USA) according to the manufacturer’s guidelines. Single-stranded cDNA was synthesized from total RNA with the PrimeScript™ RT Master Mix (TaKaRa, China). Real-time RT-PCR for each target was performed with the SYBR® Premix Ex Taq II polymerase (TaKaRa). The thermal cycling conditions were set as follows: preheating for 30 seconds at 94°C, 40 cycles of denaturation (10 seconds at 94°C), annealing (30 seconds at 60°C), and elongation (20 seconds at 72°C). For each sample, the mRNA levels were normalized to the mRNA levels of the internal control, β -actin. The pairs of primers used are listed in Table 1.


2.3. Western Blot Analysis. After the mice were sacrificed, protein was extracted; the total protein concentration in the



(a)



(b)



(c)

FIGURE 1: PET images of the BAT from Lmna^{-/-} and wild-type (WT) mice. (a) The changes of SUV_{Max} in the BAT from 4 to 16 weeks of age. (b) Lmna^{-/-} and WT mice PET/CT images at 4 weeks and 14 weeks of age. (c) Quantification of SUV_{Max} and T/NT (target/nontarget) values in the BAT of Lmna^{-/-} and WT mice at 4 and 14 weeks. Lung tissue was defined as the NT reference. **P* < 0.05; ***P* < 0.01; ****P* < 0.001.

samples was determined using the bicinchoninic acid (BCA; Boster, China) method and by adding 5 × loading buffer and then heating at 100°C for 5 min. 40 μg of protein from each

sample was loaded onto 10% sodium dodecyl sulfate-polyacrylamide 1 mm gels and transferred onto nitrocellulose (NC) membranes. To detect the target proteins, we

blocked the membranes for 2 h with 5% bovine serum albumin (BSA; Boster, Hubei, China) at 4°C. Then, the membranes were incubated overnight at 4°C with anti- β 3-AR (1:1000, Abcam, USA) antibodies or anti-UCP1 (1:1000, Cell Signaling Technology, USA) specifically recognizing the target proteins. The membranes were subsequently washed with Tris-buffered saline containing Tween-20 (TBST) for 5 min, and the process was repeated five times. Then, the membranes were incubated for 1 h at room temperature with secondary antibody. The membrane was washed five times in TBST for 5 min. Blots were exposed and developed using the enhanced chemiluminescence (ECL) method. The images were captured and analyzed by the ImageJ software.

2.4. Immunohistochemistry Analysis. The BAT was harvested from freshly sacrificed mice and fixed in 10% formalin. Formalin-fixed, paraffin-embedded tissue blocks were serially cut into 3 mm thick sections, which were dewaxed in xylene and rehydrated through a graded series of ethanol solutions. After 3 washes in PBS, heat-induced antigen was retrieved in 0.01 M citric acid buffer (pH 6.0) and autoclaved for 5 min at 120°C. Nonspecific binding sites were blocked through preincubation with normal bovine serum albumin for 30 min. Slices were washed 3 times in PBS for 5 min. These tissue sections were then incubated with anti- β 3-AR antibodies (1:100; Abcam), anti-UCP1 antibodies (1:50; Cell Signaling Technology), PRDM16 (1:100; Abcam), or p16INK4a (1:500; Abcam), which were diluted in PBST buffer containing 4% BSA and 2.5% Triton X-100. Then, the tissue slices were incubated with horseradish peroxidase-conjugated anti-rabbit IgG (1:1000; EarthOx). In all the sections, the positively labeled cells were visualized using 3,3'-diaminobenzidine tetrahydrochloride (Shanghai Sangon) as a chromogen and were counterstained with hematoxylin. Quantification of the immunostaining was performed by digital image analysis with the Image-Pro Plus 6.0 software (Media Cybernetics). A total of 3 fields of view per slice were selected for imaging hot-spot areas (400x objective lens), and 5 slices from each animal were acquired. In each imaging field, the integrated optical density (IOD) and the area of interest (AOI) of all the positively stained area were measured. The IOD was used to evaluate the area and intensity of the positive staining. The mean density (IOD/AOI) represents the concentration of a specific protein per unit area.

2.5. Evaluation of Cell Apoptosis in the Brown Adipose Tissue. Tissue apoptosis was assessed by performing the TUNEL staining (Beyotime, Beijing, China) assay on the sample slices, according to the manufacturer's protocol. Briefly, after dewaxing and hydration, sections were incubated with TUNEL reaction mixture. Nuclei were stained using DAPI. Afterwards, slides were observed using a fluorescence microscope (400x; TE-2000U, Nikon, Japan). For each staining, a total of 3 sections per group were observed.

2.6. Statistical Analysis. All values are expressed as mean \pm SEM. Statistical analysis was performed using GraphPad

Prism software. The results of PET imaging over time were compared between WT and $Lmna^{-/-}$ mice using the two-way ANOVA with post hoc test. The differences between the two groups were determined by Student's *t*-test. Differences with $P < 0.05$ were considered statistically significant.

3. Results

3.1. Effects of Age on the Metabolic Activity of BAT in Mice. To study the effect of age on $Lmna^{-/-}$ and WT mice, PET/CT imaging was performed from 4 weeks on $Lmna^{-/-}$ and WT mice, once every two weeks and for 16 weeks. As shown in Figure 1(a), there was a significant difference in PET imaging results over time between WT and $Lmna^{-/-}$ mice ($P < 0.05$). From 4 to 12 weeks, there was no significant difference in the SUV_{Max} of the BAT between $Lmna^{-/-}$ and WT mice, indicating that FDG uptake during the first 12 weeks was similar between the two mice strains. As shown in Figures 1(b) and 1(c), at the fourth week of PET imaging, there was no difference in the levels of ^{18}F -FDG uptake between $Lmna^{-/-}$ and WT mice, but at 14 weeks of age, ^{18}F -FDG uptake in the BAT of $Lmna^{-/-}$ mice was significantly lower than that in WT mice. Statistically, the SUV_{Max} value and the T/NT ratio of BAT did not differ significantly between $Lmna^{-/-}$ and WT mice at 4 weeks of age (SUV_{Max} value: 9.260 ± 0.571 versus 9.373 ± 0.709 , $P = 0.9069$; T/NT ratio: 32.27 ± 2.278 versus 30.41 ± 2.411 , $P = 0.6223$). At 14 weeks of age, both measurements in the $Lmna^{-/-}$ mice were significantly lower than those in WT mice (SUV_{Max} value: 3.673 ± 0.4613 versus 10.34 ± 0.8663 , $P = 0.0003$; T/NT ratio: 11.61 ± 1.975 versus 33.16 ± 2.687 , $P = 0.0030$). These findings confirm that the BAT ^{18}F -FDG uptake in $Lmna^{-/-}$ mice decreased significantly at 14 weeks of age.

3.2. Effects of Age on BAT in Mice. To investigate the causes of the reduction in BAT ^{18}F -FDG uptake in $Lmna^{-/-}$ mice, the mRNA expression levels of UCP1 and beta3-AR were assessed. As shown in Figure 2(b), UCP1 and beta3-AR protein levels in $Lmna^{-/-}$ mice were significantly lower than those in WT mice at 14 weeks of age (UCP1: 0.0474 ± 0.0089 versus 1.000 ± 0.0666 , $P = 0.0001$; beta3-AR: 3143 ± 0.0329 versus 1.000 ± 0.0445 , $P = 0.0002$). At 4 weeks of age, as shown in Figure 2(c), there was no difference in the mRNA expression levels of UCP1 and beta3-AR between $Lmna^{-/-}$ and WT mice (UCP1: 1.403 ± 0.1213 versus 1.342 ± 0.1959 , $P = 0.8026$; beta3-AR: 1.200 ± 0.9090 versus 1.170 ± 0.1703 , $P = 0.8223$), while at 14 weeks of age, the expression of UCP1 and beta3-AR was decreased (UCP1: 0.4854 ± 0.1012 versus 1.367 ± 0.2706 , $P = 0.0380$; beta3-AR: 0.2830 ± 0.0497 versus 1.445 ± 0.1189 , $P = 0.0008$). As shown in Figure 2(d), immunohistochemical analysis results were consistent with Western blot results. These findings show that both the protein and mRNA expression levels of UCP1 and beta3-AR, the molecular markers of BAT activity, are reduced in $Lmna^{-/-}$ mice, which is consistent with the aging characteristics of the BAT of healthy mice [21].

To study the causes of BAT dysfunction, the expression of PRDM16 was also assessed. In addition, CDKN2A/p16INK4a




FIGURE 2: Analysis of beta3-AR and UCP1 levels in the BAT of Lmna^{-/-} and WT mice. (a, b) Relative transcription levels of UCP1 and β3-AR in Lmna^{-/-} and WT mice at 4 and 14 weeks of age. (c) Western blot analysis for UCP1, beta3-AR, and β-actin and semiquantitative analysis of the expression levels of UCP1 and β3-AR. (d) BAT hematoxylin and eosin staining and immunohistochemical analysis of beta3-AR and UCP1. *P < 0.05; **P < 0.001; ***P < 0.001.

immunostaining was performed to assess cellular senescence [22], while apoptotic cells in the BAT were quantified by performing terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). As shown in Figure 3, both the protein and mRNA levels of PRDM16 were decreased at the age of 14 weeks in Lmna^{-/-} mice (1.000 ± 0.1582 versus 1.850 ± 0.0945, P = 0.0099). A significant increase in the number of p16INK4a-expressing cells was observed in the BAT of Lmna^{-/-} mice (64.33 ± 2.333% versus 50.33 ± 2.603, P = 0.0161). Likewise, the number of TUNEL-positive cells in the BAT of Lmna^{-/-} mice was higher than that in WT mice (4.0 ± 0.45% versus 1.36 ± 0.1202, P = 0.0049).

3.3. Effects of Age on the Body Weight of Mice. As shown in Figure 4, the body weight of Lmna^{-/-} mice began to decline

at the 10th week of age, while the weight of wild mice continued to increase, showing that, at that stage, the Lmna^{-/-} mice started to lose weight, indicating a decline in the metabolic state of their body.

4. Discussion

In this study, we examined the changes of BAT function in relation to age and investigated the relationship between ¹⁸F-FDG PET/CT imaging and aging in the BAT of Lmna^{-/-} mice. The mechanism of BAT dysfunction was also explored. Our study led to these major findings: Firstly, the BAT function of the Lmna^{-/-} mice significantly decreased, and the uptake of ¹⁸F-FDG was reduced at the age of 14 weeks. Secondly, the mechanism of BAT aging in Lmna^{-/-} mice is




FIGURE 3: Analysis of the PRDM16 expression levels, and cell senescence and apoptosis rates in the BAT of *Lmna*^{-/-} and WT mice. (a) Relative transcription levels and immunohistochemical analysis of PRDM16 in *Lmna*^{-/-} and WT mice at 14 weeks of age. (b, c) Images of p16INK4a immunostaining (black, open arrowheads) and TUNEL (yellow, open arrowheads) in the BAT of *Lmna*^{-/-} and WT mice and quantification of positive labeling for p16INK4a and TUNEL. * $P < 0.05$; ** $P < 0.01$.




FIGURE 4: Changes in the body weight during aging in *Lmna*^{-/-} and WT mice.

associated with a reduction in the number of brown adipocytes and an increase in the number of senescent and apoptotic cells. Thirdly, the state of the body of *Lmna*^{-/-} mice began to decline at 10 weeks of age, which is earlier than the observed ¹⁸F-FDG uptake decrease.

Aging is an irreversible natural process. It is projected that the world senior and geriatric population will reach 2.1 billion by 2050 [23]. Aging is the primary risk factor for major human pathologies, including cancer, diabetes, cardiovascular

disorders, neurodegenerative diseases [24], and is one of the most important determinants of BAT activity in all animals, from rodents to humans [25]. Since BAT activity has important physiological significance, it is of great importance to study the mechanism of BAT aging. An aging model for the study of BAT is necessary. However, there were no reported aging models suitable for BAT studies until recently [26, 27]. In our study, we found that the *Lmna*^{-/-} mice BAT displayed age-related dysfunction characteristics, which would be beneficial

for BAT aging research. Utilizing *Lmna*^{-/-} mice for studying BAT aging could resolve the problem of long study periods, inconsistent determination of aging degree, and other model-related issues.

Lmna^{-/-} mice BAT dysfunction can mimic normal mice BAT aging changes. The changes in the BAT of normal mice were predominantly associated with the reduction in the levels of β 3-AR and UCP1 [28]. We found that the expression of β 3-AR and UCP1 in *Lmna*^{-/-} mice decreased in a short time and the BAT exhibited age-related dysfunction features. The reduction in the ¹⁸F-FDG uptake in the BAT of *Lmna*^{-/-} mice was closely related to the decreased expression of β 3-AR and UCP1. Exposure to cold has been known to stimulate the sympathetic nervous system via binding of the neurotransmitter norepinephrine to the β 3-AR [29]. β 3-AR stimulation has been reported to increase glucose uptake in BAT [30] through induction of transcription and *de novo* synthesis of glucose transporter molecule 1 (GLUT1) [31]. Likewise, we also found that *Lmna*^{-/-} mice GLUT1 transcription levels were significantly lower than those in WT mice (Supplementary Figure 2). Under cold stimulation, β 3-AR not only increases glucose transport, but also promotes UCP1 expression and activity [32]. Although Hankir MK et al. proposed that BAT ¹⁸F-FDG uptake and UCP1-mediated heat production can be dissociated [33], most studies suggest that UCP1 is necessary for norepinephrine-induced glucose utilization in BAT [30]. Therefore, the reduction in the levels of UCP1 in *Lmna*^{-/-} mice was likely responsible for the reduction of ¹⁸F-FDG uptake in the BAT.

The mechanism of BAT dysfunction in *Lmna*^{-/-} mice also simulates the mechanism of BAT aging in normal mice [34]. The premature aging of the HGPS mouse model is attributed to a point mutation in position 1824 of the *Lmna* gene, which results in the conversion of cytosine to thymine in the encoded protein. This mutation creates an abnormal splice donor site, which produces a truncated protein (progerin), lacking residues 607–656 of prelamin A but retaining the C-terminal CAAX box, a target for prenylation [15]. Progerin cannot be detached from the nuclear membrane and ultimately damages the structure and function of the nucleus [35]. Progerin also participates in the normal process of aging [36, 37]. Therefore, HGPS mice exhibit an accelerated rate of a subset of pathological changes that together drive a faster aging process [24, 38]. BAT aging in *Lmna*^{-/-} mice mimicked the physiological aging of BAT in two aspects. Firstly, brown fat cell formation was reduced. This reduction was consistent with the decrease in the gene expression levels of PRDM16 in *Lmna*^{-/-} mice, which acts as a transcriptional coregulator that controls the development of brown adipocytes in BAT [39]. Secondly, the increased apoptosis and senescence rate of brown adipose tissue in *Lmna*^{-/-} mice could result in a reduction in the number of brown adipocytes, an observation which also mimics the physiological aging of BAT [40].

Aging is a systemic change, which in *Lmna*^{-/-} mice causes an early decrease in the body weight that can be observed at the 10th week of age. The mice of the HGPS model are lean [41] and display myopathic disease [42], which leads to body weight reduction earlier than the

observed BAT ¹⁸F-FDG uptake decrease, indicating that in *Lmna*^{-/-} mice, the decline in the metabolic state of the body initiates before BAT aging.

However, the results of our study have some limitations. Firstly, it should be pointed out that the aging mechanism triggered by the *Lmna*^{-/-} phenotype may not be the only reason for the altered glucose metabolism function and apoptosis process of the BAT. Progeria and other *Lmna*-linked diseases may also influence the ¹⁸F-FDG uptake in the BAT. For example, progerin has been reported to have cytotoxicity effects and to induce mitochondrial damage [43]. In addition, it has been described that *Lmna*^{-/-} mice are likely to display slow heart rates and *Lmna*-linked hypoglycemia [17], which could also inhibit ¹⁸F-FDG uptake. More research is needed to investigate the magnitude of the effect of progeria and other *Lmna*-linked diseases on the degeneration of BAT. Secondly, we studied the aging of BAT in *Lmna*^{-/-} mice from the perspective of glucose metabolism. ¹⁸F-FDG is currently considered the ‘gold standard’ for the assessment of BAT metabolic activity, but it cannot discriminate between oxidative and nonoxidative BAT glucose metabolism [44, 45]. In addition to ¹⁸F-FDG, other tracers are still available to be used for studying metabolic activity changes in the aging of BAT [46]. Therefore, for a more comprehensive assessment of the BAT metabolic activity, the application of other tracers is also required.

5. Conclusion

Lmna^{-/-} mice are an ideal model for studying BAT aging. The ¹⁸F-FDG uptake and the levels of BAT-related molecular markers were decreased in *Lmna*^{-/-} mice at 14 weeks of age. The aging characteristics and the aging mechanism of BAT in *Lmna*^{-/-} mice can mimic the normal process of BAT aging.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

Zhengjie Wang, Xiaolong Xu, Fei Kang, Baohua Liu, and Jing Wang contributed equally to this work.

Supplementary Materials

Supplementary Figure 1: identification of *Lmna*^{-/-} mice. (a) The photograph of the three kinds of mice at 14 weeks of age. Het, heterozygote; (b) *Lmna*^{-/-} mice were identified by PCR and Western blot. Progerin, the truncated type of Lamin A. Supplementary Figure 2: relative transcription levels of GLUT1 in the BAT of *Lmna*^{-/-} and WT mice. ****P* < 0.001 (Supplementary Materials)

References

- [1] B. Cannon and J. Nedergaard, “Brown adipose tissue: function and physiological significance,” *Physiological Reviews*, vol. 84, no. 1, pp. 277–359, 2004.

- [2] E. Koksharova, D. Ustyuzhanin, Y. Philippov et al., "The relationship between brown adipose tissue content in supraclavicular fat depots and insulin sensitivity in patients with type 2 diabetes mellitus and prediabetes," *Diabetes Technology and Therapeutics*, vol. 19, no. 2, pp. 96–102, 2017.
- [3] J. F. Berbee, M. R. Boon, P. P. Khedoe et al., "Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development," *Nature Communications*, vol. 6, no. 1, p. 6356, 2015.
- [4] V. Lecoultre and E. Ravussin, "Brown adipose tissue and aging," *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 14, no. 1, pp. 1–6, 2011.
- [5] T. Yoneshiro, S. Aita, M. Matsushita et al., "Age-related decrease in cold-activated brown adipose tissue and accumulation of body fat in healthy humans," *Obesity*, vol. 19, no. 9, pp. 1755–1760, 2011.
- [6] S. A. Kirov, M. I. Talan, N. A. Kosheleva, and B. T. Engel, "Nonshivering thermogenesis during acute cold exposure in adult and aged C57BL/6J mice," *Experimental Gerontology*, vol. 31, no. 3, pp. 409–419, 1996.
- [7] H. Yamashita, Y. Sato, and N. Mori, "Difference in induction of uncoupling protein genes in adipose tissues between young and old rats during cold exposure," *FEBS Letters*, vol. 458, no. 2, pp. 157–161, 1999.
- [8] L. Lin, J. H. Lee, E. D. Buras et al., "Ghrelin receptor regulates adipose tissue inflammation in aging," *Aging*, vol. 8, no. 1, pp. 178–191, 2016.
- [9] T. G. Graber, J. H. Kim, R. W. Grange, L. K. McLoon, and L. V. Thompson, "C57BL/6 life span study: age-related declines in muscle power production and contractile velocity," *Age*, vol. 37, no. 3, p. 9773, 2015.
- [10] C. Cohade, M. Osman, H. K. Pannu, and R. L. Wahl, "Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT," *Journal of Nuclear Medicine*, vol. 44, pp. 170–176, 2003.
- [11] H. W. Yeung, R. K. Grewal, M. Gonen, H. Schoder, and S. M. Larson, "Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET," *Journal of Nuclear Medicine*, vol. 44, pp. 1789–1796, 2003.
- [12] A. M. Cypess, C. R. Haft, M. R. Laughlin, and H. H. Hu, "Brown fat in humans: consensus points and experimental guidelines," *Cell Metabolism*, vol. 20, no. 3, pp. 408–415, 2014.
- [13] H. Zhang, Z. M. Xiong, and K. Cao, "Mechanisms controlling the smooth muscle cell death in progeria via down-regulation of poly(ADP-ribose) polymerase 1," *Proceedings of the National Academy of Sciences*, vol. 111, no. 22, pp. E2261–E2270, 2014.
- [14] C. Y. Chen, Y. H. Chi, R. A. Mutalif et al., "Accumulation of the inner nuclear envelope protein Sun1 is pathogenic in progeric and dystrophic laminopathies," *Cell*, vol. 149, no. 3, pp. 565–577, 2012.
- [15] A. De Sandre-Giovannoli, R. Bernard, P. Cau et al., "Lamin A truncation in Hutchinson-Gilford progeria," *Science*, vol. 300, no. 5628, p. 2055, 2003.
- [16] N. Kubben and T. Misteli, "Shared molecular and cellular mechanisms of premature ageing and ageing-associated diseases," *Nature Reviews Molecular Cell Biology*, vol. 18, no. 10, pp. 595–609, 2017.
- [17] F. G. Osorio, C. L. Navarro, J. Cadinanos et al., "Splicing-directed therapy in a new mouse model of human accelerated aging," *Science Translational Medicine*, vol. 3, no. 106, 2011.
- [18] N. J. Ullrich and L. B. Gordon, "Hutchinson-Gilford progeria syndrome," in *Handbook of Clinical Neurology*, vol. 132, pp. 249–264, Elsevier, New York, NY, USA, 2015.
- [19] H. J. Jung, C. Coffinier, Y. Choe et al., "Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA," *Proceedings of the National Academy of Sciences*, vol. 109, no. 7, pp. E423–E431, 2012.
- [20] X. Wang, L. J. Minze, and Z. Z. Shi, "Functional imaging of brown fat in mice with 18F-FDG micro-PET/CT," *Journal of Visualized Experiments*, no. 69, article e4060, 2012.
- [21] R. B. McDonald and B. A. Horwitz, "Brown adipose tissue thermogenesis during aging and senescence," *Journal of Bioenergetics and Biomembranes*, vol. 31, no. 5, pp. 507–516, 1999.
- [22] B. M. Hall, V. Balan, A. S. Gleiberman et al., "Aging of mice is associated with p16(Ink4a)- and beta-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells," *Aging*, vol. 8, no. 7, pp. 1294–1315, 2016.
- [23] C. J. Mba, "Population ageing in Ghana: research gaps and the way forward," *Journal of Aging Research*, vol. 2010, Article ID 672157, 8 pages, 2010.
- [24] C. Lopez-Otin, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, "The hallmarks of aging," *Cell*, vol. 153, no. 6, pp. 1194–1217, 2013.
- [25] L. Bahler, H. J. Verberne, W. M. Admiraal et al., "Differences in sympathetic nervous stimulation of brown adipose tissue between the young and old, and the lean and obese," *Journal of Nuclear Medicine*, vol. 57, no. 3, pp. 372–377, 2016.
- [26] B. Hemmeryckx, M. F. Hoylaerts, and H. R. Lijnen, "Effect of premature aging on murine adipose tissue," *Experimental Gerontology*, vol. 47, no. 3, pp. 256–262, 2012.
- [27] W. P. Vermeij, J. H. Hoeijmakers, and J. Pothof, "Genome integrity in aging: human syndromes, mouse models, and therapeutic options," *Annual Review of Pharmacology and Toxicology*, vol. 56, no. 1, pp. 427–445, 2016.
- [28] A. Graja and T. J. Schulz, "Mechanisms of aging-related impairment of brown adipocyte development and function," *Gerontology*, vol. 61, no. 3, pp. 211–217, 2015.
- [29] J. Himms-Hagen, A. Melnyk, M. C. Zingaretti, E. Ceresi, G. Barbatelli, and S. Cinti, "Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes," *American Journal of Physiology-Cell Physiology*, vol. 279, no. 3, pp. C670–C681, 2000.
- [30] K. Inokuma, Y. Ogura-Okamatsu, C. Toda, K. Kimura, H. Yamashita, and M. Saito, "Uncoupling protein 1 is necessary for norepinephrine-induced glucose utilization in brown adipose tissue," *Diabetes*, vol. 54, no. 5, pp. 1385–1391, 2005.
- [31] J. M. Olsen, M. Sato, O. S. Dallner et al., "Glucose uptake in brown fat cells is dependent on mTOR complex 2-promoted GLUT1 translocation," *Journal of Cell Biology*, vol. 207, no. 3, pp. 365–374, 2014.
- [32] S. Collins, E. Yehuda-Shnaidman, and H. Wang, "Positive and negative control of Ucp1 gene transcription and the role of beta-adrenergic signaling networks," *International Journal of Obesity*, vol. 34, no. 1, pp. S28–S33, 2010.
- [33] M. K. Hankir, M. Kranz, S. Keipert et al., "Dissociation between brown adipose tissue 18F-FDG uptake and thermogenesis in uncoupling protein 1 deficient mice," *Journal of Nuclear Medicine*, vol. 58, no. 7, pp. 1100–1103, 2017.
- [34] M. J. Harms, J. Ishibashi, W. Wang et al., "Prdm16 is required for the maintenance of brown adipocyte identity and function in adult mice," *Cell Metabolism*, vol. 19, no. 4, pp. 593–604, 2014.
- [35] K. Cao, J. J. Graziotto, C. D. Blair et al., "Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells," *Science Translational Medicine*, vol. 3, no. 89, 2011.

- [36] C. D. Ragnauth, D. T. Warren, Y. Liu et al., "Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging," *Circulation*, vol. 121, no. 20, pp. 2200–2210, 2010.
- [37] S. Rodriguez, F. Coppede, H. Sagelius, and M. Eriksson, "Increased expression of the Hutchinson-Gilford progeria syndrome truncated lamin A transcript during cell aging," *European Journal of Human Genetics*, vol. 17, no. 7, pp. 928–937, 2009.
- [38] C. R. Burtner and B. K. Kennedy, "Progeria syndromes and ageing: what is the connection?," *Nature Reviews Molecular Cell Biology*, vol. 11, no. 8, pp. 567–578, 2010.
- [39] P. Seale, H. M. Conroe, J. Estall et al., "Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice," *Journal of Clinical Investigation*, vol. 121, no. 1, pp. 96–105, 2011.
- [40] D. Sellayah and D. Sikder, "Orexin restores aging-related brown adipose tissue dysfunction in male mice," *Endocrinology*, vol. 155, no. 2, pp. 485–501, 2014.
- [41] T. Sullivan, D. Escalante-Alcalde, H. Bhatt et al., "Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy," *Journal of Cell Biology*, vol. 147, no. 5, pp. 913–920, 1999.
- [42] D. A. Cutler, T. Sullivan, B. Marcus-Samuels, C. L. Stewart, and M. L. Reitman, "Characterization of adiposity and metabolism in Lmna-deficient mice," *Biochemical and Biophysical Research Communications*, vol. 291, no. 3, pp. 522–527, 2002.
- [43] Z. M. Xiong, J. Y. Choi, K. Wang et al., "Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria," *Aging Cell*, vol. 15, no. 2, pp. 279–290, 2016.
- [44] J. Orava, P. Nuutila, M. E. Lidell et al., "Different metabolic responses of human brown adipose tissue to activation by cold and insulin," *Cell Metabolism*, vol. 14, no. 2, pp. 272–279, 2011.
- [45] D. P. Blondin, S. M. Labbe, C. Noll et al., "Selective impairment of glucose but not fatty acid or oxidative metabolism in brown adipose tissue of subjects with type 2 diabetes," *Diabetes*, vol. 64, no. 7, pp. 2388–2397, 2015.
- [46] M. Din, J. Raiko, T. Saari et al., "Human brown adipose tissue [(15)O]O₂ PET imaging in the presence and absence of cold stimulus," *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 43, no. 10, pp. 1878–1886, 2016.



Hindawi

Submit your manuscripts at
www.hindawi.com

